Otonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX™ in Patients with Ménière’s Disease

Back to Jobs

Achieved primary endpoint (p value = 0.029) Company plans to meet with FDA to discuss results and clinical requirements for registration Management will review results during third quarter conference call at 4:30 p.m. EST today SAN DIEGO , Nov. 08, 2017 (GLOBE NEWSWIRE) — Otonomy ,

Apply Now